• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management. It has two products in clinical development, which include Zingo and 4975. Zingo is an anesthetic that has completed two Phase 3 trials in the pediatric population for the treatment of pain associated with venipuncture and cannulation; and 4975 is an anesthetic for the treatment of site-specific moderate to severe pain, and is in multiple Phase 2 and Phase 3 trials in post-surgical and musculoskeletal pain.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
ALTA PARTNERS MANAGEMENT VIII, LLC ALTA CALIFORNIA PARTNERS III LP ALTA EMBARCADERO PARTNERS III LLC |
|
6,291,995 | 2010-01-06 | 0 |
|
6,291,995 | 2010-01-06 | 0 | |
|
TRAN JOHN H. VICE PRESIDENT, FINANCE |
|
0 | 2009-05-07 | 0 |
|
0 | 2009-02-12 | 0 | |
|
HOUGHTON WILLIAM C CHIEF MEDICAL OFFICER |
|
0 | 2008-12-03 | 0 |
|
VIRET JEAN-FREDERIC VP AND CHIEF FINANCIAL OFFICER |
|
0 | 2008-12-03 | 0 |
|
KRANDA MICHAEL L PRESIDENT AND CEO |
|
0 | 2008-12-03 | 0 |
|
DONAHUE NANCY E SR. VP, MARKETING & SALES |
|
22,651 | 2008-10-14 | 0 |
|
CAMPBELL JAMES N |
|
188,000 | 2008-09-08 | 0 |
|
No longer subject to file | 2008-06-25 | 0 | |
|
3,369,029 | 2008-05-13 | 0 | |
|
3,369,063 | 2008-05-13 | 0 | |
|
4,907,038 | 2008-05-09 | 0 | |
|
ECKERT CARTER H |
|
13,258 | 2008-05-09 | 0 |
|
4,806,917 | 2008-05-09 | 0 | |
|
0 | 2008-05-09 | 0 | |
|
2,500 | 2008-05-09 | 0 | |
|
9,030 | 2008-05-09 | 0 | |
|
MCLAUGHLIN JOHN PETER CHIEF EXECUTIVE OFFICER |
|
128,024 | 2008-02-07 | 0 |
|
BRODERICK PATRICK A VP & GENERAL COUNSEL |
|
16,460 | 2008-02-06 | 0 |
|
REGAN JOHN X. SR. VP OPERATIONS |
|
16,318 | 2008-02-06 | 0 |
|
ALTA PARTNERS MANAGEMENT VIII, LLC ALTA CALIFORNIA PARTNERS III LP ALTA CALIFORNIA MANAGEMENT PARTNERS III LLC ALTA EMBARCADERO PARTNERS III LLC |
|
6,696,645 | 2007-12-18 | 0 |
|
SOFINNOVA VENTURE PARTNERS V LP SOFINNOVA VENTURE AFFILIATES V LP SOFINNOVA VENTURE PRINCIPALS V LP SOFINNOVA MANAGEMENT V 2005, LLC |
|
4,906,973 | 2007-12-18 | 0 |
|
SOFINNOVA VENTURE PARTNERS V LP SOFINNOVA VENTURE AFFILIATES V LP SOFINNOVA VENTURE PRINCIPALS V LP |
|
4,906,973 | 2007-12-18 | 0 |
|
4,812,183 | 2007-12-18 | 0 | |
|
4,797,273 | 2007-12-18 | 0 | |
|
JP MORGAN PARTNERS GLOBAL INVESTORS LP J P MORGAN PARTNERS GLOBAL INVESTORS A LP J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP |
|
3,451,529 | 2007-05-31 | 0 |
|
10,000 | 2007-05-31 | 0 | |
|
HUANG JAMES Z PRESIDENT |
|
48,173 | 2006-12-04 | 0 |
|
JPMP CAPITAL LLC JP MORGAN PARTNERS GLOBAL INVESTORS LP J P MORGAN PARTNERS GLOBAL INVESTORS A LP J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP |
|
3,441,529 | 2006-06-22 | 0 |
|
POWERS RICHARD P VP & CHIEF FINANCIAL OFFICER |
|
106,597 | 2006-05-10 | 0 |
|
BURCH RONALD M FORMER VP, DEVELOPMENT |
|
26,645 | 2006-04-18 | 0 |
|
2,823,661 | 2006-02-28 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
